STAT July 15, 2024
Morning! Today, we look at some promising, but early, gene therapy data from Lexeo Therapeutics, examine Medicare’s new price negotiation rules and their impact on innovation, and more.
Lexeo’s gene therapy for rare heart disease looks promising
Lexeo Therapeutics is developing a gene therapy meant to prevent deadly heart complications in patients with Friedreich’s ataxia, a rare genetic disorder of the heart. The results are early and inconclusive but promising — and Lexeo is optimistic that it could win FDA approval, after another study.
“In my opinion, it sits squarely in the type of framework that Peter Marks has been sort of driving,” Lexeo CEO Nolan Townsend told STAT’s Jason Mast, speaking of the director of the agency’s biologics division.
...Today's Sponsors
Today's Sponsor